XML 39 R28.htm IDEA: XBRL DOCUMENT v3.25.3
Segment Reporting (Tables)
9 Months Ended
Sep. 30, 2025
Segment Reporting  
Schedule of segment significant expense categories

    

Nine Months Ended September 30, 

2025

2024

Grant income

$

13,407

$

16,516

Less:

 

 

Clinical programs

16,486

22,312

R&D Personnel costs(1)

6,221

7,520

Preclinical programs

262

784

Manufacturing

1,901

1,926

Other research and development expenses

222

176

General and administrative expenses(2)

7,307

7,311

Equity-based compensation

1,729

3,214

Other segment items(3)

 

(577)

 

(598)

Segment and consolidated net loss

$

(20,144)

$

(26,129)

(1) R&D Personnel costs exclude equity-based compensation

(2) General and administrative expenses exclude equity-based compensation

(3) Other segment items include, Other income, net, Interest expense and Loss on currency translation from liquidation of subsidiary.